Excessive vasoconstriction after stress by the aging kidney: inadequate prostaglandin modulation of increased endothelin activity. 1998

S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
Istituto di Clinica Medica Generale e Cardiologia, Dipartimento di Fisiopatologia Clinica, Università di Firenze, Italy.

The adaptive capacity of the aging kidney to stimulation of the sympathetic nervous system, as induced by a 30-minute mental stress (MS), was assessed in 8 elderly healthy women (68 to 82 years of age) and compared with that of 8 younger women (24 to 40 years of age). The study encompassed 4 consecutive 30-minute periods (baseline, mental stress, recovery 1, and recovery 2). In the elderly subjects, baseline effective renal plasma flow (ERPF)(iodine 131-labeled hippurate clearance) was lower and glomerular filtration rate (GFR)(iodine 125-labeled iothalamate clearance) was proportionally less reduced than in the younger group; the filtration fraction (FF) was higher. The elderly group excreted more endothelin 1 (ET-1) (P < .05), prostaglandin E2 (PGE2), and 6-keto-prostaglandin F1alpha (6-keto PGF1alpha)(P < .001 for both)(radioimmunoassay). Mental stress induced similar increases in blood pressure, heart rate, and plasma catecholamines in the 2 age groups, limited to the stimulation period. In the elderly group, mental stress caused a prolonged decrease in ERPF that reached its maximum 60 minutes after mental stress (-33%, P < .05), while GFR remained constant during the whole experiment, so that FF increased. In the younger subjects, renal hemodynamic changes were limited to the mental stress period. ET-1 increased during mental stress and the first recovery period in the elderly group (+50% and +25%, P < .05) as it did in the younger group, but the elderly group differed from the younger in that vasodilating prostaglandins increased only during mental stress. In conclusion, the aging kidney reacts to adrenergic stimulation with more-pronounced and -prolonged vasoconstriction that is probably caused by a defect in prostaglandin modulation of endothelin activity. Autoregulation of GFR is maintained at the expense of increased intraglomerular pressure.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D006157 Guanosine Monophosphate A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. 5'-Guanylic Acid,Guanosine 5'-Monophosphate,5'-GMP,Guanylic Acid,5' Guanylic Acid,5'-Monophosphate, Guanosine,Acid, 5'-Guanylic,Acid, Guanylic,Guanosine 5' Monophosphate,Monophosphate, Guanosine
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
March 1985, The Journal of pharmacology and experimental therapeutics,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
October 1990, Biochemistry international,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
June 1980, The American journal of physiology,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
August 1996, Journal of hypertension,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
February 2012, British journal of pharmacology,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
January 1993, Journal of cardiovascular pharmacology,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
February 1978, Science (New York, N.Y.),
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
January 2000, American journal of hypertension,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
January 2019, Oxidative medicine and cellular longevity,
S Castellani, and A Ungar, and C Cantini, and G La Cava, and C Di Serio, and A Altobelli, and B Vallotti, and M Pellegri, and A Brocchi, and A Camaiti, and M Coppo, and U Meldolesi, and G Messeri, and G Masotti
January 1990, Advances in second messenger and phosphoprotein research,
Copied contents to your clipboard!